2 weeks Ago By Defense World Staff
Shares of 89bio, Inc. ( NASDAQ:ETNB – Get Free Report ) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company.
The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $30.33. ETNB has been the topic of several analyst reports.
Raymond James lowered their price target on shares of 89bio from $53.00 to $49.00 and set a “strong-buy” rating on the stock in a report on Friday, November 8th.
HC Wainwright reissued a “buy” rating and issued a $29.00 price target on shares of 89bio in a research report on Monday. Cantor Fitzgerald restated an “overweight” rating and set a $29.
00 price target on shares of 89bio in a research note on Friday, September 20th. Finally, Royal Bank of Canada lowered their price objective on 89bio from $13.00 to $12.
00 and set a “sector perform” rating on the stock in a research note on Tuesday, August 6th. Check Out Our Latest Stock Report on 89bio Institutional Trading of 89bio 89bio Stock Performance ETNB opened at $8.75 on Tuesday.
The stock’s 50 day simple moving average is $8.20 and its 200-day simple moving average is $8.42.
The company has a current ratio of 11.66, a quick ratio of 11.66 and a debt-to-equity ratio of 0.
09. The stock has a market cap of $928.64 million, a PE ratio of -3.
06 and a beta of 1.07. 89bio has a 1 year low of $7.
00 and a 1 year high of $16.63. 89bio Company Profile ( Get Free Report 89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. Featured Articles Five stocks we like better than 89bio Breakout Stocks: What They Are and How to Identify Them 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours? Mouse Rising: The Iger Investment Pays Off for Disney Investors Consumer Discretionary Stocks Explained Can CAVA Stock Be the Next Chipotle? Earnings Can Help Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.
com's FREE daily email newsletter ..
